GV
GV Management Company, LLC, formerly known as Google Ventures, serves as the venture capital arm of Alphabet Inc., established in 2009 and headquartered in Mountain View, California, with additional offices in Boston, New York, Cambridge, and London. The firm specializes in growth capital investments across various stages, including seed, early, mid, and late stages, focusing on sectors such as life sciences, healthcare, artificial intelligence, robotics, cyber security, and agriculture. GV has invested in over 300 companies, seeking to support startups that aim to innovate and transform industries. The firm typically invests up to $50 million, with smaller amounts allocated to early-stage ventures. GV provides its portfolio companies with exceptional support by connecting them with Google's resources and talent, leveraging a team of experts in engineering, design, science, and marketing to enhance their growth potential.
Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to create innovative treatments that address the underlying causes of mitochondrial issues. By leveraging a comprehensive understanding of mitochondrial mechanisms, Pretzel Therapeutics seeks to reverse dysfunction at its roots, potentially providing effective solutions for patients suffering from a range of conditions, including those related to aging. The company's name reflects its scientific focus on the mitochondrion, which is characterized by its unique and highly folded inner membrane, distinguishing it from other organelles in the body.
TMRW Life Sciences is a developer of a cryo-storage platform intended to improve the success rates of assisted reproductive technology. The company's platform offers an in-clinic robotic storage system and a fully digital chain of custody from clinic to offsite longterm storage, continuous remote and local monitoring and electronically integrated processes characterized by digital health signals received from every oocyte and embryo daily, enabling clients to streamline embryology lab operations, eliminate manual steps and integrates digital quality control.
Monte Rosa Therapeutics is a biotechnology company based in Basel, Switzerland, that specializes in developing innovative cancer therapeutics through the modulation of protein degradation pathways. The company focuses on molecular glue degraders (MGDs), a class of small molecule drugs that utilize the body's natural mechanisms for protein degradation to selectively target and degrade proteins relevant to cancer treatment. Monte Rosa employs its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, to identify and develop target proteins for degradation. With a library of over 50,000 MGD molecules, its leading product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing potential for treating MYC-driven tumors. The company is committed to advancing its pipeline of novel therapeutics to address unmet medical needs in oncology.
TScan Therapeutics is a biopharmaceutical company dedicated to developing innovative T cell therapies to treat various cancers, including liquid tumors and solid tumors. The company focuses on engineering T cell receptor (TCR) therapies, with specific candidates aimed at addressing hematologic malignancies and preventing relapse after hematopoietic stem cell transplantation. TScan utilizes a specialized platform that identifies shared T cell antigens and minimizes off-target effects, enhancing the safety and effectiveness of its treatments. The company’s pipeline includes both liquid tumor therapies and multiplexed TCR-T candidates for solid tumors. Founded in 2018, TScan Therapeutics is headquartered in Waltham, Massachusetts, and comprises a team of experts committed to expanding treatment options for patients with limited therapeutic alternatives.
Monte Rosa Therapeutics is a biotechnology company based in Basel, Switzerland, that specializes in developing innovative cancer therapeutics through the modulation of protein degradation pathways. The company focuses on molecular glue degraders (MGDs), a class of small molecule drugs that utilize the body's natural mechanisms for protein degradation to selectively target and degrade proteins relevant to cancer treatment. Monte Rosa employs its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, to identify and develop target proteins for degradation. With a library of over 50,000 MGD molecules, its leading product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing potential for treating MYC-driven tumors. The company is committed to advancing its pipeline of novel therapeutics to address unmet medical needs in oncology.
TScan Therapeutics is a biopharmaceutical company dedicated to developing innovative T cell therapies to treat various cancers, including liquid tumors and solid tumors. The company focuses on engineering T cell receptor (TCR) therapies, with specific candidates aimed at addressing hematologic malignancies and preventing relapse after hematopoietic stem cell transplantation. TScan utilizes a specialized platform that identifies shared T cell antigens and minimizes off-target effects, enhancing the safety and effectiveness of its treatments. The company’s pipeline includes both liquid tumor therapies and multiplexed TCR-T candidates for solid tumors. Founded in 2018, TScan Therapeutics is headquartered in Waltham, Massachusetts, and comprises a team of experts committed to expanding treatment options for patients with limited therapeutic alternatives.
TScan Therapeutics is a biopharmaceutical company dedicated to developing innovative T cell therapies to treat various cancers, including liquid tumors and solid tumors. The company focuses on engineering T cell receptor (TCR) therapies, with specific candidates aimed at addressing hematologic malignancies and preventing relapse after hematopoietic stem cell transplantation. TScan utilizes a specialized platform that identifies shared T cell antigens and minimizes off-target effects, enhancing the safety and effectiveness of its treatments. The company’s pipeline includes both liquid tumor therapies and multiplexed TCR-T candidates for solid tumors. Founded in 2018, TScan Therapeutics is headquartered in Waltham, Massachusetts, and comprises a team of experts committed to expanding treatment options for patients with limited therapeutic alternatives.
Maze Therapeutics is a biotechnology company based in South San Francisco, California, that specializes in the development of genetic modifier therapeutics. Founded in 2017 and formerly known as Modulus Therapeutics, the company is dedicated to translating genetic insights into innovative medicines. Maze Therapeutics utilizes a comprehensive approach that integrates large-scale human genetics data, functional genomics, and various drug discovery methodologies. This approach allows the company to identify modifier genes that offer protection against diseases, enhancing the understanding of target biology and informing drug development strategies. By leveraging these insights, Maze Therapeutics aims to facilitate the creation of novel therapies that can benefit patients.
Tamr is an enterprise data unification company that is cost-effective, scalable, and accessible to any enterprise.
Following the success of initial research at MIT CSAIL, the Tamr team began building a commercial-grade solution designed to tackle the challenge of connecting and enriching diverse data at scale, quickly and cost effectively.
Launched in the spring of 2014 and backed by a series of investors, such as Google Ventures and New Enterprise Associates, Tamr is deployed in production at a variety organizations, including information services providers, pharmaceutical firms and retailers. Tamr, based in Cambridge, Massachusetts, was founded in 2013 by database industry veterans Andy Palmer, Mike Stonebraker and Ihab Ilyas with George Beskales, Daniel Bruckner and Alex Pagan.
The Players' Tribune (TPT) is a first-of-its-kind content and technology platform that was developed by athletes for athletes to connect them with fans through the power of storytelling. By giving athletes the tools to create truly personal content and tell their stories, The Players’ Tribune is reimagining the world of sports and culture through the player’s point of view. More than 2,000 athletes have contributed to the platform through impactful and powerful long and short-form stories, video series, and audio. It was founded by Derek Jeter in 2014, TPT provides unique insight into the daily sports conversation and brings fans closer than ever to the games they love.
Tamr is an enterprise data unification company that is cost-effective, scalable, and accessible to any enterprise.
Following the success of initial research at MIT CSAIL, the Tamr team began building a commercial-grade solution designed to tackle the challenge of connecting and enriching diverse data at scale, quickly and cost effectively.
Launched in the spring of 2014 and backed by a series of investors, such as Google Ventures and New Enterprise Associates, Tamr is deployed in production at a variety organizations, including information services providers, pharmaceutical firms and retailers. Tamr, based in Cambridge, Massachusetts, was founded in 2013 by database industry veterans Andy Palmer, Mike Stonebraker and Ihab Ilyas with George Beskales, Daniel Bruckner and Alex Pagan.
Tamr is an enterprise data unification company that is cost-effective, scalable, and accessible to any enterprise.
Following the success of initial research at MIT CSAIL, the Tamr team began building a commercial-grade solution designed to tackle the challenge of connecting and enriching diverse data at scale, quickly and cost effectively.
Launched in the spring of 2014 and backed by a series of investors, such as Google Ventures and New Enterprise Associates, Tamr is deployed in production at a variety organizations, including information services providers, pharmaceutical firms and retailers. Tamr, based in Cambridge, Massachusetts, was founded in 2013 by database industry veterans Andy Palmer, Mike Stonebraker and Ihab Ilyas with George Beskales, Daniel Bruckner and Alex Pagan.
Miso Media is a Venice Beach, CA startup who develops music education software. They use polyphonic note detection and realtime feedback to revolutionize sheet music and teach people how to play string instruments such as guitar, bass, ukulele, banjo, and mandolin. Current products include Miso Music: Plectrum (Winner of 2010 TechCrunch Disrupt SF People’s Choice Award) and the Miso Strobe Tuner. They have strategic partnerships with Fender, Fender Music Foundation, Woodees, Deering Banjo, and Ko'Aloha Ukulele, as well as publishing deals for the production of digitized sheet music.
tenXer is the company redefining personal productivity by building a platform that allows any employee to analyze their daily work habits. tenXer CEO and Founder Jeff Ma is the inspiration for both the movie 21 and the book Bringing Down the House. Ma created the concept for tenXer when he saw a huge opportunity in the human capital management industry. tenXer focuses first and foremost on the everyday individual worker; the employee opposed to upper management. The company built a proprietary, data-driven platform that enables employees to better understand and improve their work performance, allowing them to be more intrinsically motivated and therefore more productive.
Miso Media is a Venice Beach, CA startup who develops music education software. They use polyphonic note detection and realtime feedback to revolutionize sheet music and teach people how to play string instruments such as guitar, bass, ukulele, banjo, and mandolin. Current products include Miso Music: Plectrum (Winner of 2010 TechCrunch Disrupt SF People’s Choice Award) and the Miso Strobe Tuner. They have strategic partnerships with Fender, Fender Music Foundation, Woodees, Deering Banjo, and Ko'Aloha Ukulele, as well as publishing deals for the production of digitized sheet music.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.